Recent News & Research

*June 2023* EGFR Resisters and LCRF are delighted to update supporters about the research made possible by their partnership! The EGFR Resisters Grant was awarded in 2021 to Yang Tian, PhD, Icahn School of Medicine at Mount Sinai. She joins us along with Hideo Watanabe, MD, PhD, who leads The Watanabe…

*May 2023* Long-term data from the CHRYSALIS trial (NCT02609776) continued to demonstrate clinical benefit for amivantamabvmjw (Rybrevant), according to findings presented at the European Lung Cancer Congress 2023 in Copenhagen, Denmark.1 At a median follow-up of 19.2 months, median progression-free survival (PFS) with the agent was 6.9 months (95% CI,…

*May 2023* Nearly half of all brain tumors are associated with an underlying cancer diagnosis, and lung cancer is one of the most common of these. As improved cancer therapies are helping patients live longer, the safe and effective management of lung cancer brain metastases is coming to the fore.…

*May 2023* The emergence of immune checkpoint inhibitors has dramatically altered the treatment landscape of stage IV NSCLC with some patients now experiencing unprecedented long-term survival after PD-1/PD-L1 therapy. These individuals that benefit typically have smoking-induced lung tumors, while patients who have never smoked or have EGFR-driven NSCLC, generally possess…

*May 2023* Positive findings from the FLAURA2 study add to the body of evidence supporting treatment with osimertinib for patients with EGFRm non–small cell lung cancer.mpared to osimertinib alone and as such, can further delay treatment resistance and disease progression.” The combination of osimertinib (Tagrisso) with chemotherapy generated a statistically significant…

*May 2023* Antibody Drug Conjugates (ADCs) are a novel class of therapeutic that structurally comprise an antibody directed at a tumor epitope connected via a linker to a cytotoxic payload that have shown significant antitumor activity across a range of malignancies including lung cancer. In this article we review the…

*April 2023* The discussion then shifted to liquid and tissue biopsies. Liquid biopsies, which involve looking for abnormal DNA in the blood, are described as a great tool for patients whose tumors are shedding into their bloodstream. However, a negative result does not necessarily mean that there's no mutation, as…

*June 2023* Purpose:The uncommon EGFR exon 19 deletion (ex19del), L747_A750>P, demonstrates reduced sensitivity to osimertinib compared with the common ex19del, E746_A750del in preclinical models. The clinical efficacy of osimertinib in patients with non–small cell lung cancer harboring L747_A750>P and other uncommon ex19dels is not known. Design:The AACR GENIE database was interrogated to…

*April 2023* A complete understanding of how exposure to environmental substances promotes cancer formation is lacking. More than 70 years ago, tumorigenesis was proposed to occur in a two-step process: an initiating step that induces mutations in healthy cells, followed by a promoter step that triggers cancer development1. Here we propose…